Global peptic ulcer drugs market 2017-2021


◆タイトル:Global peptic ulcer drugs market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥381,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥545,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Peptic Ulcer DrugsA peptic ulcer is an open lesion, which develops on the mucosal lining of the stomach and the small intestine due to the caustic effect of the gastric acid and pepsin present in these organs. The general symptoms of a peptic ulcer include abdominal pain, nausea, vomiting, and bloated stomach. The specific symptom of peptic ulcer is the bleeding of the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. It is caused mainly by the Helicobacter pylori bacteria followed by the overuse of over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen, aspirin, and ibuprofen.

Technavio’s analysts forecast the global peptic ulcer drugs market to grow at a CAGR of 2.80% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global peptic ulcer drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Peptic Ulcer Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca,
• Daewoong Pharmaceuticals,
• Eisai,
• Takeda Pharmaceutical

[Other prominent vendors]
• GlaxoSmithKline
• Pfizer

[Market driver]
• Economics of treating ulcer
• For a full, detailed list, view our report

[Market challenge]
• Adverse effect of PPIs
• For a full, detailed list, view our report

[Market trend]
• Bismuth-based quadruple therapy
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Peptic ulcers: Disease overview

PART 06: Key clinical trials

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by drug class
• PPIs
• Antibiotics
• Others

PART 09: Geographical segmentation
• Peptic ulcer drugs market in Americas
• Peptic ulcer drugs market in EMEA
• Peptic ulcer drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Bismuth-based quadruple therapy
• Emergence of monotherapy
• Recurrent H. pylori infections
• Rise in awareness

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• AstraZeneca
• Daewoong Pharmaceuticals
• Eisai
• Takeda Pharmaceutical
• Other prominent vendors

PART 15: Appendix
• List of abbreviations


AstraZeneca, Daewoong Pharmaceuticals, Eisai, and Takeda Pharmaceutical.GlaxoSmithKline and Pfizer.





★調査レポート[消化性潰瘍治療薬の世界市場2017-2021] (Global peptic ulcer drugs market 2017-2021 / IRTNTR13352)販売に関する免責事項
[消化性潰瘍治療薬の世界市場2017-2021] (Global peptic ulcer drugs market 2017-2021 / IRTNTR13352)についてEメールでお問い合わせ